ERIS Lifescience (ERIS)
FAST GROWERFairStock Score: 57/100 — STEADY
Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹1,392.8 |
| Market Cap | ₹18,815.61 Cr |
| P/E Ratio | 42.42 |
| ROCE | 12.22% |
| ROE | 15.13% |
| Dividend Yield | 0.54% |
| Profit Growth | 30.95% |
| Debt/Equity | 0.77 |
| Sales Growth | 12.37% |
| Free Cash Flow | ₹98,700 Cr |
| Promoter Holding | 54.85% |
| 52-Week Range | ₹1,236 — ₹1,910 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹206.06 |
ERIS Lifescience trades with a P/E ratio of 42.42, ROCE of 12.22%, ROE of 15.13%, profit growth of 30.95%, debt-to-equity of 0.77. The FairStock Score of 57/100 suggests mixed fundamentals — some metrics look solid while others need improvement.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer